Thursday, May 19, 2022 7:34:23 PM
Reefrad, I haven’t kept up with with board so I appreciate you sharing your conversation, and I apologize if I wasn’t very clear. I agree with your characterization of Dave as genuine and honest, and I think he is extremely knowledgable about the industry and markets, which is why I find it curious that he said that “the clinical trials update is a nothing burger and meaningless.“
I personally think that updating the clinical trials registry is a pretty big deal, and I believe it’s a prerequisite for the journal article, so I’m not sure why he is saying that it’s not related and is downplaying the significance. The timing of the update occurred when it did for a reason, and I don’t believe that it was just some afterthought to clear things up. Northwest Bio has been slow and deliberative in their actions and disclosures. So whether it’s for regulatory reasons, or they are gathering evidence for an investigation, or something else, I think there are likely valid reasons for the way things have played out this past week, but it appears Dave and Northwest Bio are not able to disclose this right now, and perhaps don’t want to draw attention to it.
I personally think that updating the clinical trials registry is a pretty big deal, and I believe it’s a prerequisite for the journal article, so I’m not sure why he is saying that it’s not related and is downplaying the significance. The timing of the update occurred when it did for a reason, and I don’t believe that it was just some afterthought to clear things up. Northwest Bio has been slow and deliberative in their actions and disclosures. So whether it’s for regulatory reasons, or they are gathering evidence for an investigation, or something else, I think there are likely valid reasons for the way things have played out this past week, but it appears Dave and Northwest Bio are not able to disclose this right now, and perhaps don’t want to draw attention to it.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
